Medicine (Baltimore). 2026 Jun 12;105(24):e49298. doi: 10.1097/MD.0000000000049298.
ABSTRACT
This study aimed to explore the diagnostic value of combining serologic indexes with the Gleason score (GS) in identifying prostate cancer bone metastasis. We included 108 patients diagnosed with prostate cancer at the Third Hospital of Mianyang from December 2019 to December 2021. Clinical data were collected, and patients were divided into 2 groups: 44 cases with prostate cancer bone metastasis and 64 cases without bone metastasis. We compared age, serum total prostate-specific antigen (TPSA), free prostate-specific antigen (FPSA), fibrinogen (FIB), alkaline phosphatase (ALP), serum albumin (ALB), and GS between the 2 groups. Logistic regression analysis was used to assess the correlation between serologic indexes and prostate cancer bone metastasis. The diagnostic value of combining multiple indexes versus single indexes was evaluated using receiver operating characteristic curves. The serum TPSA, FPSA, FIB, ALP and GS levels of patients in the prostate cancer bone metastasis group were higher than those of patients in the prostate cancer without bone metastasis group, while the ALB level in the bone metastasis group was lower than that in the non-bone metastasis group. The differences in each index were statistically significant when compared between the 2 groups (P < .05). The univariate logistic analysis revealed that TPSA (OR:0.984, P < .001), FPSA (OR:0.899, P < .001), ALP (OR:0.986, P < .05), and GS (OR:0.569, P < .05) were positively correlated with prostate cancer bone metastasis. Multivariate analysis showed that ALP (OR = 0.991, P < .05) was an independent risk factor for bone metastasis in prostate cancer after adjusting for Age, ALB, and FIB. The area under the receiver operating characteristic curve (AUC) of serum ALP and the combined assay were 0.738 and 0.792, respectively. Serum TPSA, FPSA, FIB, ALB, ALP and GS have significant diagnostic value in identifying prostate cancer bone metastasis. ALP is an independent risk factor for bone metastasis in prostate cancer. Combining these indicators can enhance diagnostic efficacy.
PMID:42299585 | DOI:10.1097/MD.0000000000049298
